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External validation of binary clinical risk-prediction models is vital. We provide 30	
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INTRODUCTION 34	
Clinical risk-prediction models (CRPMs, also known as prognostic models or 35	
risk score models) serve an important role in healthcare,1 particularly for binary 36	
adverse events (in-hospital, 30-day, or operative mortality) after cardiac, thoracic, 37	
and vascular surgery. These models may be applied to 3 different objectives: 1) to 38	
assess patient risk, which surgeons and patients can then factor in to healthcare 39	
decisions; 2) to stratify risk, both for clinical decision-making and inclusion criteria in 40	
a controlled randomized trial,2 and 3) to assess and compare healthcare outcomes 41	
among providers (benchmarking). The comparison of observed with expected 42	
outcomes, accounting for statistical uncertainty, can identify underperforming 43	
healthcare providers for quality improvement interventions.3 44	
The wide-ranging importance of CRPMs in the cardiovascular specialty 45	
means that stakeholders must have confidence in them. A poorly performing model 46	
can lead to suboptimal decision-making, misinformed patients, false reassurance of 47	
a healthcare provider’s performance, or false stigmatization of the provider. 48	
Confidence is established by validating the model.4  49	
Model validation can be internal, temporal, or external. Internal model 50	
validation is one element of CRPM development, usually published alongside the 51	
model to confirm the model performs well for the training data. External validation, 52	
which evaluates the generalizability (or transportability) of the model to other groups 53	
of patients, is fundamental to demonstrating a model is appropriate for adoption in 54	
clinical practice.4 In cardiovascular and thoracic surgery, the majority of CRPMs 55	
encountered will predict binary outcomes, which were created using multivariable 56	
regression techniques, in particular logistic regression. Therefore, we focus our 57	
discussion to this area. However, the general principles and need for external 58	
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validation apply to other outcome types and models, e.g. time-to-event data,5,6 as 59	
well as to non-regression techniques, e.g. machine learning approaches.7 60	
 61	
MODEL PERFORMANCE CONCEPTS 62	
Performance of CRPMs is typically based on assessing two important 63	
features: calibration and discrimination.6 64	
Calibration is the accuracy of the model for predicting events relative to 65	
observed events in groups of patients. For example, if the mean predicted event 66	
occurrence is 5% in a patient group, but the observed event occurrence is 10%, then 67	
we conclude the model is not well calibrated because it underpredicts. 68	
Discrimination is the ability of a model to distinguish between patients who 69	
experienced the event and those who did not. Discrimination is measured using the 70	
area under the receiver-operating-characteristic curve (AUROC), also referred to as 71	
the concordance (c-)statistic or c-index.5 This value has a meaningful interpretation. 72	
If we randomly select 2 patients, 1 who experienced the event and 1 who did not, 73	
then the AUROC is equivalent to the probability that the risk score attributed to the 74	
former is greater than that attributed to the latter. An AUROC of 1 indicates perfect 75	
classification; a value of 0.5 is equivalent to tossing a fair coin. 76	
Other aspects of performance assessment include clinical usefulness, 77	
impact,8 and overall performance measures such as the Brier score9 and 78	
concordance index, particularly for time-related events. 79	
 80	
DESIGNING AND REPORTING AN EXTERNAL VALIDATION 81	
When designing a validation study, thought must be given to several key 82	
elements. 83	
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Selection of patients. The selection of patients used to externally validate a 84	
CRPM might differ from those used to develop the model. These differences might 85	
be temporal or geographical, or related to clinical setting, inclusion or exclusion 86	
criteria, definitions, diagnostic techniques, or inherent baseline case-mix differences 87	
between the two populations. It is important to highlight any differences that might 88	
affect model transportability between the validation and original study sample, 89	
particularly with validation of general all-surgery models (e.g. the EuroSCORE) 90	
within procedural10 or operative subgroups.11 91	
Risk factor data. It goes without saying that calculating a risk score requires 92	
access to all variables that comprise the risk score. One potential issue is conflict in 93	
variable definitions. For example, a registry that only collects binary data on whether 94	
pulmonary artery (PA) systolic pressure is >60 mmHg (a risk factor in the logistic 95	
EuroSCORE model) would not be able to compute the EuroSCORE II risk score, 96	
which includes model coefficients for PA systolic pressures of 31 – 55 mmHg and 97	
>55 mmHg. This is primarily an issue for retrospective validation studies, as clinical 98	
registries can be updated to capture contemporary risk-score data. 99	
Missing data. One cannot calculate a risk score without access to data for 100	
variables that comprise the CRPM. If a model contains a risk factor such as 101	
preoperative serum creatinine, but these data are sparsely available in the dataset, 102	
then in many cases the risk score cannot be calculated. Case-complete analyses—103	
those that delete subjects with missing data for required variables—might lead to 104	
bias if those subjects are not representative of the whole population.12 In certain 105	
cases, reasonable estimates and assumptions can be made based on clinical 106	
expertise or additional information in the dataset. For example, a number of variables 107	
in Society of Thoracic Surgeons (STS) risk models have coefficients set to 0 for 108	
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some variables in some models; if one is validating such a model, missing data for 109	
such a variable is of no consequence. Alternatively, statistical imputation or subset 110	
analysis techniques might be applied to compensate.13,14 If a validation study 111	
specifically excludes certain groups of patients (for example, emergency surgery, 112	
reoperations, or endocarditis), imputation of 0 is an accurate and appropriate 113	
substitution, but the validation is only partial. In any case, it is always necessary to 114	
summarize the frequency of missing data and present methods for managing it and 115	
its assumptions. 116	
Sample size. Considerations regarding sample size should not be limited to 117	
randomized control trials. Single-center validation studies will often have a limited 118	
pool of subjects, especially for subgroup analyses, and increasing the sample size 119	
will require widening the study period, which could come at a price (see comment on 120	
calibration drift below). When designing a study, sample size (number of subjects) 121	
alone is not enough; one must also consider effective sample size (number of 122	
events). Relatively little attention has been given to this matter, but some studies 123	
have recommended a minimum of 100 events and 100 non-events for validation 124	
studies, and in certain applications, larger effective sizes will be required to obtain 125	
adequate power.15,16 126	
Outcome definitions. Many well-known CRPMs in cardiac surgery predict 127	
early or operative mortality, including the logistic EuroSCORE17 and STS Cardiac 128	
Surgery Risk Models.18–20 Operative mortality is generally accepted to mean death 129	
within 30 days (or later if the patient has not been discharged within 30 days).21 130	
However, other definitions of mortality exist, such as in-hospital mortality.22 Two 131	
large databases reported operative mortality to be 4.63% and 3.57%, compared with 132	
in-hospital mortality of 4.02% and 2.94%, respectively.23,24 In both cases, in-hospital 133	
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mortality was approximately 0.6% lower. In-hospital mortality is generally easier to 134	
robustly measure, whereas 30-day mortality requires post-discharge follow-up for 135	
most patients.25 Therefore, it is common to see models validated against in-hospital 136	
mortality. In this example, we would expect the model to over-predict mortality 137	
relative to the observed data. It is reasonable to assess the model performance for 138	
this similar endpoint; however, this subtlety should be borne in mind when designing 139	
a study, particularly if the objective of the study is to compare models that have 140	
different outcome definitions. Similar considerations apply to cases where the 141	
definition of a major postoperative complication used for model development differs 142	
from that in the validation dataset. 143	
Large study windows. One simple way to increase sample size in a 144	
validation study is to widen the study window. However, validation of a CRPM over a 145	
substantially wide period can introduce a number of complexities. One potential 146	
issue is calibration drift.26,27 Multiple studies demonstrated that the ratio of observed 147	
mortality to mean logistic EuroSCORE was decreasing with time. Changing risk 148	
profiles, other variables influencing mortality, and changes in the association of risk 149	
factors with outcome can all contribute to this phenomenon. This prompted the 150	
introduction of the EuroSCORE II model23 and the series of contemporary STS 151	
models.18–20 Researchers should be aware of this, particularly when validating 152	
cardiac surgery CRPMs. 153	
TRIPOD statement. In recent years, reporting of biomedical research has 154	
been improved with guidelines such as the CONSORT statement28 for randomized 155	
trials and the PRISMA statement29 for systematic reviews and meta-analyses. 156	
Prompted by evidence of poor quality reporting in the CRPM literature, the recent 157	
TRIPOD statement describes reporting guidelines for studies developing, validating, 158	
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or updating a prediction model.30 We strongly encourage researchers to follow these 159	
guidelines and make use of the checklist for validating models. Examples of good 160	
practice and additional details have been previously published.31 161	
 162	
METHODS FOR ASSESSING CALIBRATION 163	
Hosmer-Lemeshow test. The Hosmer-Lemeshow test is a frequently 164	
reported statistical test for assessing calibration in CRPMs. However, it has a 165	
number of drawbacks.31–35 First, it is not easily interpreted; that is, it does not provide 166	
a measure of the magnitude of any miscalibration. Second, for slight deviations in 167	
calibration, the test is sensitive to sample size. Third, the classical version of the test 168	
is dependent on arbitrary groupings of patients. In some cases, the Hosmer-169	
Lemeshow test remains a useful adjunct statistic, but should only be included as part 170	
of a more comprehensive assessment. Typically, the Hosmer-Lemeshow test refers 171	
to a test based on 10 groups composed by deciles of risk. However, authors should 172	
be aware that there are variations on the test with regard to groupings (quantiles vs. 173	
fixed cut-points), number of groups (g), degrees of freedom of the chi-squared 174	
statistic (g-2 for internal vs. g for external validation), and software 175	
implementations.35,36 While g is typically selected to be 10, one must ensure the cell 176	
counts are sufficient to justify the distributional approximation. Including a table of 177	
observed and expected events by binning group provides a useful summary, and 178	
allows for inspection of each term for fit, as recommended by Hosmer and 179	
Lemeshow (p. 188).36 180	
Calibration plot. If a standard Hosmer-Lemeshow test is performed, then a 181	
simple graph—the calibration plot—is a straightforward next step (Figure).4 Within 182	
each of the g groups, observed events are plotted against expected events. If the 183	
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model is well calibrated, then these points should be close to the 45° line. The 184	
calibration plot can be augmented by overlaying a non-parametric smoothing curve 185	
(e.g. loess) through the observed and predicted data37 or a calibration curve.38 186	
Contrary to the Hosmer-Lemeshow test and basic calibration plot, these additional 187	
fits are not dependent on arbitrary groupings. 188	
Calibration curves. Cox’s calibration regression fits a logistic regression 189	
between the observed event and the log-odds transformed predicted values.39 A 190	
perfectly calibrated CRPM (deriving from a logistic regression model) yields an 191	
intercept = 0 and a slope = 1. These fitted regression models can be superimposed 192	
onto a calibration plot, giving an alternative graphical description of the 193	
miscalibration. As well as quantifying the degree of miscalibration, one can also 194	
simultaneously test whether the estimated parameters reject the null hypothesis of 195	
calibration. There are other related null hypotheses that can be tested for assessing 196	
calibration also (p. 274).6 197	
Other tests. The Hosmer-Lemeshow is ubiquitous in biomedical CRPM 198	
literature. However, researchers can take advantage of a wide variety of statistical 199	
tests to assess model validation, such as the aforementioned calibration curve 200	
test(s), the Spiegelhalter Z-test,40 and methods proposed by Stallard.41 Most can be 201	
calculated using routine software packages.6,38 There is no omnibus test of 202	
calibration; each approach has different merits and limitations. Therefore, it is 203	
important that researchers employ a broad repertoire of methods to address the 204	
study questions. 205	
 206	
MODEL UPDATING 207	
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A natural extension to the validation of a CRPM is the concept of updating an 208	
existing model. This might involve exploring whether a new biomarker improves a 209	
model (e.g. using net reclassification improvement measures42), recalibrating a 210	
model,43 and, more recently, assessing whether multiple models can be combined to 211	
provide a more accurate prediction (e.g. meta-models and model averaging).44 This 212	
expanding research area is especially important in an era of personalized 213	
medicine.45 214	
 215	
CONCLUSIONS 216	
External validation of CRPMs is necessary to demonstrate their predictive 217	
accuracy. Available models have likely been validated internally; however, using 218	
them in different settings, locations, and populations can result in relatively poor 219	
performance. CRPMs that have been overfitted during development will also often 220	
fail to generalise to the external validation sample. Calibration and discrimination 221	
must be measured in order to establish validity. There are multiple statistical 222	
approaches available to interrogate the calibration, with it being widely accepted that 223	
the ubiquitous Hosmer-Lemeshow test has limited utility. Execution of a rigorous 224	
CRPM validation study rests in proper study design, application of suitable statistical 225	
methods, and transparent reporting. 226	
  227	
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FIGURE LEGEND 363	
Figure. A calibration plot for simulated data (n = 500). The green triangles denote 364	
the mean predicted and observed event probabilities for patients grouped into tenths 365	
using deciles. The grey dashed line denotes perfect calibration. A smoothing curve 366	
(blue dashed line) and the calibration curve (red solid line) are also overlaid. The 367	
distribution of calculated predicted probabilities is overlaid along the horizontal axis. 368	
A subset of various statistics useful for validating the model are also shown. This 369	
figure was generated using standard statistical software: the rms package for R (R 370	
Core Team, R Foundation for Statistical Computing, Vienna, Austria; version 3.1.2). 371	
Further details are given in Harrell (2001)38 and Harrell (2015).46 Code to reproduce 372	
this plot is given in the Appendix. 373	
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APPENDIX 375	
R code to produce figure 376	
# If ‘rms’ package not install, run command 377	
# install.packages(“rms”) 378	
library(rms) 379	
## Simulate fake data: 380	
##   y = binary outcome 381	
##   x1, x2, x3 = covariates in the risk model 382	
##   n = sample size 383	
set.seed(1) 384	
n <- 1000 # 500 development + 500 validation 385	
x1 <- runif(n) # covariate 1 386	
x2 <- runif(n) # covariate 2 387	
x3 <- runif(n) # covariate 3 388	
logit <- -5 + 0.5*x1 + 2*x2 + 3.5*x3 389	
P <- 1 / (1 + exp(-logit)) 390	
y <- ifelse(runif(n) <= P, 1, 0) # outcomes 391	
d <- data.frame(x1, x2, x3, y) # combined dataset 392	
 393	
## Fit a risk prediction model to first half of the data 394	
f <- lrm(y ~ x1 + x2 + x3, subset = 1:500) 395	
 396	
## Use model to get predictions for second half of data 397	
pred.logit <- predict(f, d[501:1000, ]) 398	
phat <- 1 / (1 + exp(-pred.logit)) 399	
 400	
## Validate prediction 401	
val.prob(phat, y[501:1000], g = 10, riskdist = “predicted”) 402	
